ID   T122
AC   CVCL_C7W0
DR   Wikidata; Q123033594
RX   PubMed=27723895;
CC   Doubling time: 27.86 +- 3.71 hours (Note=At 6-11th passages), 20.47 +- 2.23 hours (Note=At 60-62th passages) (PubMed=27723895).
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): PubMed=27723895
ST   Amelogenin: X
ST   D10S1248: 14
ST   D12S391: 19
ST   D19S433: 14,15
ST   D1S1656: 11,12
ST   D22S1045: 15
ST   D2S1338: 19
ST   D2S441: 11
ST   D6S1043: 11
ST   TH01: 6,7
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 29-06-23; Last updated: 10-04-25; Version: 3
//
RX   PubMed=27723895; DOI=10.1167/iovs.16-19317;
RA   Mouriaux, Frederic
RA   Zaniolo, Karine
RA   Bergeron, Marjorie-Allison
RA   Weidmann, Cindy
RA   de la Fouchardiere, Arnaud
RA   Fournier, Frederic
RA   Droit, Arnaud
RA   Morcos, Mohib W.
RA   Landreville, Solange
RA   Guerin, Sylvain L.
RT   "Effects of long-term serial passaging on the characteristics and
RT   properties of cell lines derived from uveal melanoma primary
RT   tumors.";
RL   Invest. Ophthalmol. Vis. Sci. 57:5288-5301(2016).
//